Bionomics and Merck enter new research colloboration

25-Jun-2014 - Australia

Bionomics Limited announced that it has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. 

Under the agreement, Merck will fund all research and development, including clinical development, and will be responsible for worldwide commercialisation of any products from the collaboration. Bionomics will receive upfront payments totalling US$20 million and is eligible to receive up to US$506 million for achievement of certain research and clinical development milestones and undisclosed royalties on any product sales.

 “We are very excited to work with Merck to progress new therapies for cognitive impairment in conditions such as Alzheimer’s disease,” said Dr Deborah Rathjen, CEO & Managing Director of Bionomics. “We believe that the combination of Bionomics’ innovative approach and technologies, within its ionX platform, has the potential to rapidly advance new treatments.”

BNC375 is a key compound from the Bionomics research program licensed to Merck under this latest agreement. BNC375 and related compounds have displayed potent efficacy in animal cognitive impairment models.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances